NEW ENTERPRISE ASSOCIATES 15, L.P. - MILLENDO THERAPEUTICS, INC. 13D

Company

Tempest Therapeutics, Inc.

Filed

December 18, 2018

Accession Number

0001072613-18-000563

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →